RxDoctor Payments Data

Megan Manthe, MD

Orthopaedic Surgery · Ozark, MONPI 1104050772

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $35,456 of the $45,207 with a category attached, or 78.4%. Medical Device Business Services, Inc. accounts for 79.1% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $39,113, more than ten times the $2,192 reported in 2019.

$45,207in general payments, 2019–2025

Across 71 payments — averaging $636.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$36K
  • Depuy Synthes Products, Inc.$6K
  • Johnson & Johnson$3K
  • Zimmer Biomet$163
  • Stryker$26
  • Pacira Pharmaceuticals Incorporated$24
  • plus $45 from 2 others

What the payments were for

  • Consulting fees$35,45678%
  • Travel & lodging$7,43616%
  • Food & beverage$2,3145%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,207 in reported general payments places this provider in the 85th percentile of 455 orthopaedic surgery providers in Missouri.

See all orthopaedic surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$237,938
Medicare patients
413
Services billed
1,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$12,304
Tranexamic Acid248$4,013
Oxycodone Hcl511$3,087
Duloxetine Hcl126$1,270
Pregabalin19$927
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen49$395
Gabapentin28$304
Meloxicam67$279
Morphine Sulfate16$201
Tramadol Hcl59$176
Levofloxacin24$150
Ondansetron Hcl13$130
Tizanidine Hcl27$90
Morphine Sulfate ErMorphine Sulfate12$75
Cephalexin43$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$12,30437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 455 orthopaedic surgery providers in Missouri.

Other orthopaedic surgery in Ozark

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →